Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
CorrectionErratum

Correction to “Identification of AICP as a GluN2C-Selective N-Methyl-D-Aspartate Receptor Superagonist at the GluN1 Glycine Site”

Molecular Pharmacology October 2018, 94 (4) 1101-1102; DOI: https://doi.org/10.1124/mol.117.108944err
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

In the above article [Jessen M, Frederiksen K, Yi F, Clausen RP, Hansen KB, Bräuner-Osborne H, Kilburn P, and Damholt A (2017) Mol. Pharmacol 92(2): 151-161; doi: https://doi.org/10.1124/mol.117.108944 ], the authors discovered a few errors along with panels B in Figure 2 and 4 are incorrect. The x-axis for GluN1/2C in Figure 2B is a factor 10 too low. The highest concentration tested was 1000 nM and not 100 nM. In figure 4B, the concentration for GluN1/2D should have been shown as µM (the same as for GluN1/2A, GluN1/2B, and GluN1/2C) and not as nM. The following errors and Figure 2 and 4 have been corrected as displayed below and in the PDF and HTML versions of this article. The authors regret these errors and any inconvenience they may have caused.

  • Legend to Figure 2A: “10 AICP” should be “10 µM AICP”.

  • Legend to Figure 2B: “subtypes in in the presence” should be “subtypes in the presence”.

  • Page 154: It is stated that EC50 values of DCS are 110- to 570-fold higher (i.e., lower potencies) than the corresponding EC50 values of AICP. This is incorrect and should be 120- to 2600-fold higher.

  • Page 155: “mutations in GluN1 (F484L + T518L)” should be “mutations in GluN1 (F484A + T518L)”.

  • Page 155: It is stated that the potency of AICP was dramatically reduced (130- to 10,000-fold) at mutant GluN1/2A and GluN1/2C receptors compared with the respective wild-type receptors. This is incorrect and should be 140- to 10,000-fold reduced.

  • Legend to Figure 6D: “τdeactivationn” should be “τdeactivation”.

  • Legend to Figure 7: “mean ± S.E.M.” should be “mean ± S.D.”.

  • Page 160: It is stated that the GluN2 ATD could influence the interface between GluN1 and GluN2 agonist binding domains and thereby prohibit or enable interactions formed by Gln800 in GluN2B and Glu790 in GluN2C. This is incorrect and should be Gln800 in GluN2C and Glu790 in GluN2B.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

  • Copyright © 2018 The American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 94 (4)
Molecular Pharmacology
Vol. 94, Issue 4
1 Oct 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correction to “Identification of AICP as a GluN2C-Selective N-Methyl-D-Aspartate Receptor Superagonist at the GluN1 Glycine Site”
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CorrectionErratum

Correction to “Identification of AICP as a GluN2C-Selective N-Methyl-D-Aspartate Receptor Superagonist at the GluN1 Glycine Site”

Molecular Pharmacology October 1, 2018, 94 (4) 1101-1102; DOI: https://doi.org/10.1124/mol.117.108944err

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
CorrectionErratum

Correction to “Identification of AICP as a GluN2C-Selective N-Methyl-D-Aspartate Receptor Superagonist at the GluN1 Glycine Site”

Molecular Pharmacology October 1, 2018, 94 (4) 1101-1102; DOI: https://doi.org/10.1124/mol.117.108944err
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Correction to “Analgesic α-Conotoxin Binding Site on the Human GABAB Receptor”
  • Correction to “Activation of the Orphan G Protein–Coupled Receptor GPR27 by Surrogate Ligands Promotes β-Arrestin 2 Recruitment”
  • Correction to “The Intracellular N-Terminal Domain of the Acid-Sensing Ion Channel 1a Participates in Channel Opening and Membrane Expression”
Show more Erratum

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics